253 related articles for article (PubMed ID: 33989112)
1. Protein kinase inhibitors for the treatment of prostate cancer.
Chau V; Madan RA; Aragon-Ching JB
Expert Opin Pharmacother; 2021 Oct; 22(14):1889-1899. PubMed ID: 33989112
[TBL] [Abstract][Full Text] [Related]
2. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
3. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
Jia S; Gao X; Lee SH; Maira SM; Wu X; Stack EC; Signoretti S; Loda M; Zhao JJ; Roberts TM
Cancer Discov; 2013 Jan; 3(1):44-51. PubMed ID: 23258246
[TBL] [Abstract][Full Text] [Related]
4. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Sweeney C; Bracarda S; Sternberg CN; Chi KN; Olmos D; Sandhu S; Massard C; Matsubara N; Alekseev B; Parnis F; Atduev V; Buchschacher GL; Gafanov R; Corrales L; Borre M; Stroyakovskiy D; Alves GV; Bournakis E; Puente J; Harle-Yge ML; Gallo J; Chen G; Hanover J; Wongchenko MJ; Garcia J; de Bono JS
Lancet; 2021 Jul; 398(10295):131-142. PubMed ID: 34246347
[TBL] [Abstract][Full Text] [Related]
5. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Fay AP; Albiges L; Bellmunt J
Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.
Morgan TM; Koreckij TD; Corey E
Curr Cancer Drug Targets; 2009 Mar; 9(2):237-49. PubMed ID: 19275762
[TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis for the treatment of prostate cancer.
Antonarakis ES; Carducci MA
Expert Opin Ther Targets; 2012 Apr; 16(4):365-76. PubMed ID: 22413953
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
Ojemuyiwa MA; Madan RA; Dahut WL
Expert Opin Emerg Drugs; 2014 Dec; 19(4):459-70. PubMed ID: 25345821
[TBL] [Abstract][Full Text] [Related]
10. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.
Lee RJ; Smith MR
Cancer J; 2013; 19(1):90-8. PubMed ID: 23337762
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
12. Targeting fibroblast growth factor pathways in prostate cancer.
Corn PG; Wang F; McKeehan WL; Navone N
Clin Cancer Res; 2013 Nov; 19(21):5856-66. PubMed ID: 24052019
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
Pinto A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
[TBL] [Abstract][Full Text] [Related]
15. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
GrĂ¼llich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
17. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract][Full Text] [Related]
18. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
19. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
20. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]